Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Patricia P Harlow"'
Autor:
Patricia P Harlow, Susan M. Spitz, Mark S. Forsythe, Ruth R. Wexler, Martha H. Corjay, Joseph J. Petraitis, Peter J. Bouchard, Gregory C. Houghton, Shaker A. Mousa, Prabhakar K. Jadhav, Frank A. Barbera, Douglas G. Batt, Dilip P. Modi, Gary A. Cain
Publikováno v:
Journal of Medicinal Chemistry. 43:41-58
A new series of indazole-containing αvβ3 integrin antagonists is described. Starting with lead compound 18a, variations in a number of structural features were explored with respect to inhibition of the binding of β3-transfected 293 cells to fibri
Autor:
Patricia P Harlow, Solomon Ka, Smallheer Jm, Martha H. Corjay, Ruth R. Wexler, Pitts William J, Prabhakar K. Jadhav, Shaker A. Mousa, Buynitsky Js, John Wityak, James W. Jetter, Tobin Ae
Publikováno v:
Journal of Medicinal Chemistry. 43:27-40
Starting with lead compound 2, we sought to increase the selectivity for αvβ3-mediated cell adhesion by examining the effects of structural changes in both the guanidine mimetic and the substituent α to the carboxylate. To prepare some of the desi
Autor:
Janet S Kerr, Andrea J. Robinson, Candy Robinson, Hui-Yin Li, Roseanne S Wexler, George A. Boswell, Candice M. Krauthauser, Patricia P Harlow
Publikováno v:
Thrombosis Research. 88:127-136
Racemic sodium warfarin, Coumadin,® is widely used in the prevention of thromboembolic disease. The present study was undertaken to characterize three novel classes of warfarin analogs, and to compare them with the warfarin enantiomers. All three cl
Autor:
Patricia P Harlow, Andrea J. Robinson, Janet S Kerr, Roseanne S Wexler, Zhi-Yi Zhang, Laurence S. Kaminsky, Hui-Yin Li
Publikováno v:
Thrombosis research. 88(4)
Human metabolism of the S-warfarin enantiomer is catalyzed primarily by cytochrome P4502C9 (CYP2C9), which, because of the enzyme's broad drug substrate specificity, leads to drug-S-warfarin interactions. Several warfarin analogs have been synthesize
Autor:
Stephens ML; Johns Hopkins University, Baltimore, MD, USA. mstephen@jhsph.edu, Andersen M, Becker RA, Betts K, Boekelheide K, Carney E, Chapin R, Devlin D, Fitzpatrick S, Fowle JR 3rd, Harlow P, Hartung T, Hoffmann S, Holsapple M, Jacobs A, Judson R, Naidenko O, Pastoor T, Patlewicz G, Rowan A, Scherer R, Shaikh R, Simon T, Wolf D, Zurlo J
Publikováno v:
ALTEX [ALTEX] 2013; Vol. 30 (1), pp. 74-103.
Autor:
Dieterle F; Novartis Pharma AG, Basel, Switzerland. frank.dieterle@novartis.com, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, Baer W, Senagore A, Schipper MJ, Vonderscher J, Sultana S, Gerhold DL, Phillips JA, Maurer G, Carl K, Laurie D, Harpur E, Sonee M, Ennulat D, Holder D, Andrews-Cleavenger D, Gu YZ, Thompson KL, Goering PL, Vidal JM, Abadie E, Maciulaitis R, Jacobson-Kram D, Defelice AF, Hausner EA, Blank M, Thompson A, Harlow P, Throckmorton D, Xiao S, Xu N, Taylor W, Vamvakas S, Flamion B, Lima BS, Kasper P, Pasanen M, Prasad K, Troth S, Bounous D, Robinson-Gravatt D, Betton G, Davis MA, Akunda J, McDuffie JE, Suter L, Obert L, Guffroy M, Pinches M, Jayadev S, Blomme EA, Beushausen SA, Barlow VG, Collins N, Waring J, Honor D, Snook S, Lee J, Rossi P, Walker E, Mattes W
Publikováno v:
Nature biotechnology [Nat Biotechnol] 2010 May; Vol. 28 (5), pp. 455-62. Date of Electronic Publication: 2010 May 10.
Autor:
Hausner E; Food and Drug Administration, Silver Spring, Maryland, USA., Fiszman ML, Hanig J, Harlow P, Zornberg G, Sobel S
Publikováno v:
Drug safety [Drug Saf] 2008; Vol. 31 (12), pp. 1083-96.